论文部分内容阅读
本文报告20例原发性肝癌,70例肝硬化和36例健康人的血浆总补体活性(CH_(50))测定结果,初步探讨原发性肝癌患者CH_(50)测定的临床意义。对象与方法;原发性肝癌根据典型临床表现、AFP动态观察、肝同位素扫描等项诊断,其中硬化型肝癌13例、非硬化型肝癌7例。70例肝硬化均系肝功能失代偿期患者。血浆CH_(50)的测定均于采血后4小时之内,用试管溶血法进行。结果与讨论:1.健康对照组:平均CH_(50)值为26.98±4.84μ/ml (X±SD),正常值范围为19.00—35.00μ/ml。2.肝硬化组;平均CH_(50)值为18.03±6.75μ/ml。CH_(50)低于正常范围者占55.7%,无1例高于正常范围者。3.原发性肝癌组:平均CH_(50)值为
In this paper, the plasma total complement activity (CH_ (50)) was measured in 20 patients with primary liver cancer, 70 patients with cirrhosis and 36 healthy individuals. The clinical significance of CH_ (50) in patients with primary liver cancer was analyzed. Subjects and methods; primary liver cancer was diagnosed according to typical clinical manifestations, AFP dynamic observation and liver isotope scan, among which 13 were sclerosis liver cancer and 7 non-sclerosis liver cancer. 70 cases of liver cirrhosis are patients with decompensated liver function. Plasma CH_ (50) were determined within 4 hours after blood sampling, using tube hemolytic method. Results and discussion: 1. Healthy control group: The average CH_ (50) value was 26.98 ± 4.84μ / ml (X ± SD), the normal range was 19.00-35.00μ / ml. Liver cirrhosis group; mean CH_ (50) value was 18.03 ± 6.75μ / ml. CH_ (50) below the normal range accounted for 55.7%, no one higher than the normal range. 3. Primary liver cancer group: the average CH_ (50) value is